Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis.
Bacillus Calmette-Guérin
Bladder cancer
Cystectomy
Treatment failure
Urinary tract
Journal
Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
17
06
2021
accepted:
08
11
2021
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
8
10
2022
Statut:
ppublish
Résumé
This study examined real-world treatment and management of bacillus Calmette-Guérin (BCG)-unresponsive patients across 3 continents, including patients unable or unwilling to undergo cystectomy. Physicians actively involved in managing patients with nonmuscle invasive bladder cancer completed online case report forms for their 5 consecutive patients from the broad BCG-unresponsive population and a further 5 consecutive BCG-unresponsive patients who did not undergo cystectomy (in Japan, physicians provided a total of 5 patients across both cohorts). Most patients had received 1 (37%) or 2 (24%) maintenance courses of BCG. Five or more maintenance BCG courses were received by patients in Japan (59%) and China (31%), while in Germany 76% of patients received only 1 course. Most patients became BCG-unresponsive during their first (44%) or second (22%) treatment course; in Germany, 77% became BCG-unresponsive during their first treatment course. Most countries did not provide another course of BCG after a patient first became unresponsive, whereas unresponsive patients in Japan and China were most likely to be retreated with BCG. "Untreated - on watch and wait" was the main treatment/management approach received post-BCG treatment for 42% or more of patients in most countries except China (39%) and the United States (36%). "Following treatment guidelines" was consistently the top reason for post-BCG treatment selection across all treatment options. This study confirmed the global unmet need for patients with nonmuscle invasive bladder cancer, and found that many patients experienced periods of no treatment after not responding to BCG therapy.
Sections du résumé
Background
UNASSIGNED
This study examined real-world treatment and management of bacillus Calmette-Guérin (BCG)-unresponsive patients across 3 continents, including patients unable or unwilling to undergo cystectomy.
Materials and methods
UNASSIGNED
Physicians actively involved in managing patients with nonmuscle invasive bladder cancer completed online case report forms for their 5 consecutive patients from the broad BCG-unresponsive population and a further 5 consecutive BCG-unresponsive patients who did not undergo cystectomy (in Japan, physicians provided a total of 5 patients across both cohorts).
Results
UNASSIGNED
Most patients had received 1 (37%) or 2 (24%) maintenance courses of BCG. Five or more maintenance BCG courses were received by patients in Japan (59%) and China (31%), while in Germany 76% of patients received only 1 course. Most patients became BCG-unresponsive during their first (44%) or second (22%) treatment course; in Germany, 77% became BCG-unresponsive during their first treatment course. Most countries did not provide another course of BCG after a patient first became unresponsive, whereas unresponsive patients in Japan and China were most likely to be retreated with BCG. "Untreated - on watch and wait" was the main treatment/management approach received post-BCG treatment for 42% or more of patients in most countries except China (39%) and the United States (36%). "Following treatment guidelines" was consistently the top reason for post-BCG treatment selection across all treatment options.
Conclusions
UNASSIGNED
This study confirmed the global unmet need for patients with nonmuscle invasive bladder cancer, and found that many patients experienced periods of no treatment after not responding to BCG therapy.
Identifiants
pubmed: 36204362
doi: 10.1097/CU9.0000000000000072
pii: CURR-UROL_220056
pmc: PMC9527932
doi:
Types de publication
Journal Article
Langues
eng
Pagination
147-153Informations de copyright
Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc.
Références
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Int J Urol. 2020 Feb;27(2):108-116
pubmed: 31793703
J Urol. 2018 Mar;199(3):669-675
pubmed: 28882404
Eur Urol. 2020 Sep;78(3):387-399
pubmed: 32143924
Bladder Cancer. 2018 Jul 30;4(3):247-259
pubmed: 30112436
Bladder Cancer. 2018 Oct 29;4(4):395-401
pubmed: 30417050
BJU Int. 2017 Mar;119(3):371-380
pubmed: 28058776
ScientificWorldJournal. 2011 Mar 07;11:602-13
pubmed: 21399857
Investig Clin Urol. 2018 Sep;59(5):285-296
pubmed: 30182073
Can Urol Assoc J. 2010 Feb;4(1):56-64
pubmed: 20165581
Curr Opin Urol. 2020 Jul;30(4):584-593
pubmed: 32304379
Urol Oncol. 2020 Oct;38(10):774-782
pubmed: 32654948
Ecancermedicalscience. 2019 Feb 26;13:905
pubmed: 30915163
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354
pubmed: 32135513
Asian J Urol. 2015 Apr;2(2):63-69
pubmed: 29264122
Bladder Cancer. 2017 Oct 27;3(4):269-281
pubmed: 29152551
Can Urol Assoc J. 2020 Jun;14(6):204-213
pubmed: 31977307
Nat Rev Urol. 2017 Apr;14(4):244-255
pubmed: 28248951